ARTICLE | Finance
Plus: New capital for CytoReason, Truvian and Renalys
By Stephen Hansen, Director of Biopharma Intelligence
July 18, 2024 11:14 PM UTC
Five biotechs raised nearly $800 million in venture rounds over the course of two days this week — and the majority were growth financings from crossover investors.
Cardiovascular play Cardurion Pharmaceuticals Inc. brought in the largest of the rounds, announcing Wednesday it had raised $260 million in a series B led by Ascenta Capital. According to BioCentury’s BCIQ database, the financing was the seventh largest disclosed venture round so far this year…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/653007/venture-report-five-biotechs-raise-nearly-800m-in-two-day-flurry